Drug Trial Radar · NCT00471237
A Phase II Study Evaluating SB-751689 in Post-Menopausal Women With Osteoporosis.
Last checked: Nov 20, 2026Latest source record: Nov 7, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
564
Actual
Start
May 14, 2007
Primary completion
Dec 26, 2008
Study completion Dec 26, 2008
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- May 9, 2007
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years, up to 79 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a 12 month study designed to evaluate the safety and effectiveness of SB-751689 in the treatment of osteoporosis in post-menopausal women, in comparison with 2 active comparators and placebo.
Conditions
- Osteoporosis
Interventions
RonacaleretDrug
100mg, 200mg, 300mg, 400mg
TeriparatideDrug
PTH (1-34)
AlendronateDrug
Bisphosphonate
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change From Baseline in Bone Marrow Density (BMD) at Month 12 Measured by Dual-Energy X-Ray Absorptiometry (DXA) Scans of the Lumbar Spine (L1-L4)Time frame: Baseline (Day 0) and 12 Months
- Number of Participants With HypercalcemiaTime frame: Up to Month 12
- Number of Participants Withdrew Due to HypercalcemiaTime frame: Up to Month 12
- Number of Participant With Laboratory Abnormalities of Potential Clinical Concern at Any Post-baseline VisitTime frame: Up to Month 12
- Number of Participant With Vital Signs of Potential Clinical Concern at Any Post-baseline VisitTime frame: Up to 12 Months
- Number of Participant With Electrocardiogram (ECG) Findings Reported as Adverse EventTime frame: Up to 12 months
- Mean Change From Baseline in HeightTime frame: Baseline (Day 0), Month 6, 12 and early withdrawal
- Mean Change From Baseline in WeightTime frame: Baseline (Day 0), Month 6, 12 and early withdrawal
Locations
49 sites in 14 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Oakland, California
GSK Investigational Site
Palm Desert, California
GSK Investigational Site
Walnut Creek, California
GSK Investigational Site
Decatur, Georgia
GSK Investigational Site
Bethesda, Maryland
GSK Investigational Site
Akron, Ohio
GSK Investigational Site
Cleveland, Ohio
GSK Investigational Site
Portland, Oregon
GSK Investigational Site
Duncansville, Pennsylvania
GSK Investigational Site
Buenos Aires, Argentina
GSK Investigational Site
Buenos Aires, Argentina
GSK Investigational Site
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
GSK Investigational Site
St Leonards, New South Wales, Australia
GSK Investigational Site
Footscray, Victoria, Australia
GSK Investigational Site
Geelong, Victoria, Australia
GSK Investigational Site
Heidelberg, Victoria, Australia
GSK Investigational Site
Ghent, Belgium
GSK Investigational Site
Liège, Belgium
GSK Investigational Site
Tienen, Belgium
GSK Investigational Site
Ballerup Municipality, Denmark
GSK Investigational Site
Berlin, Germany
GSK Investigational Site
Berlin, Germany
GSK Investigational Site
Berlin, Germany
GSK Investigational Site
Berlin, Germany
GSK Investigational Site
Hamburg, Germany
GSK Investigational Site
Hamburg, Germany
GSK Investigational Site
Frankfurt am Main, Hesse, Germany
GSK Investigational Site
Hong Kong, Hong Kong
GSK Investigational Site
Shatin, Hong Kong
GSK Investigational Site
Mexico City, Mexico
GSK Investigational Site
Bergen, Norway
GSK Investigational Site
Hamar, Norway
GSK Investigational Site
Oslo, Norway
GSK Investigational Site
Grudziądz, Poland
GSK Investigational Site
Warsaw, Poland
GSK Investigational Site
Wroclaw, Poland
GSK Investigational Site
Moscow, Russia
GSK Investigational Site
Moscow, Russia
GSK Investigational Site
Panorama, South Africa
GSK Investigational Site
Rosebank, South Africa
Showing 40 of 49 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.